187 related articles for article (PubMed ID: 34332211)
21. Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3Kδ in Mature B-cell Malignancies.
Cooney JD; Lin AP; Jiang D; Wang L; Suhasini AN; Myers J; Qiu Z; Wölfler A; Sill H; Aguiar RCT
Clin Cancer Res; 2018 Mar; 24(5):1103-1113. PubMed ID: 29246942
[No Abstract] [Full Text] [Related]
22. TYM-3-98, a novel selective inhibitor of PI3Kδ, demonstrates promising preclinical antitumor activity in B-cell lymphomas.
Lou SY; Zheng FL; Tang YM; Zheng YN; Lu J; An H; Zhang EJ; Cui SL; Zhao HJ
Life Sci; 2024 Jun; 347():122662. PubMed ID: 38670450
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and biological evaluation of 4-(piperid-3-yl)amino substituted 6-pyridylquinazolines as potent PI3Kδ inhibitors.
Feng Y; Duan W; Fan S; Zhang H; Zhang SQ; Xin M
Bioorg Med Chem; 2019 Oct; 27(19):115035. PubMed ID: 31434616
[TBL] [Abstract][Full Text] [Related]
24. PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.
Yahiaoui A; Meadows SA; Sorensen RA; Cui ZH; Keegan KS; Brockett R; Chen G; Quéva C; Li L; Tannheimer SL
PLoS One; 2017; 12(2):e0171221. PubMed ID: 28178345
[TBL] [Abstract][Full Text] [Related]
25. Structural optimization towards promising β-methyl-4-acrylamido quinoline derivatives as PI3K/mTOR dual inhibitors for anti-cancer therapy: The in vitro and in vivo biological evaluation.
He R; Xu B; Ping L; Lv X
Eur J Med Chem; 2021 Mar; 214():113249. PubMed ID: 33561608
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis and biological evaluation of novel benzothiadiazine derivatives as potent PI3Kδ-selective inhibitors for treating B-cell-mediated malignancies.
Ma X; Wei J; Wang C; Gu D; Hu Y; Sheng R
Eur J Med Chem; 2019 May; 170():112-125. PubMed ID: 30878826
[TBL] [Abstract][Full Text] [Related]
27. Discovery of a Potent and Selective PI3Kδ Inhibitor (
Shukla MR; Patra S; Verma M; Sadasivam G; Jana N; Mahangare SJ; Vidhate P; Lagad D; Tarage A; Cheemala M; Kulkarni C; Bhagwat S; Chaudhari VD; Sayyed M; Pachpute V; Phadtare R; Gole G; Phukan S; Sunkara B; Samant C; Shingare M; Naik A; Trivedi S; Marisetti AK; Reddy M; Gholve M; Mahajan N; Sabde S; Patil V; Modi D; Mehta M; Nigade P; Tamane K; Tota S; Goyal H; Volam H; Pawar S; Ahirrao P; Dinchhana L; Mallurwar S; Akarte A; Bokare A; Kanhere R; Reddy N; Koul S; Dandekar M; Singh M; Bernstein PR; Narasimham L; Bhonde M; Gundu J; Goel R; Kulkarni S; Sharma S; Kamboj RK; Palle VP
J Med Chem; 2020 Dec; 63(23):14700-14723. PubMed ID: 33297683
[TBL] [Abstract][Full Text] [Related]
28. Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
Cheng C; Yun F; He J; Ullah S; Yuan Q
Eur J Med Chem; 2019 Jul; 173():185-202. PubMed ID: 31003060
[TBL] [Abstract][Full Text] [Related]
29. Design and synthesis of 1,4-substituted 1H-1,2,3-triazolo-quinazolin-4(3H)-ones by Huisgen 1,3-dipolar cycloaddition with PI3Kγ isoform selective activity.
Srinivas M; Singh Pathania A; Mahajan P; Verma PK; Chobe SS; Malik FA; Nargotra A; Vishwakarma RA; Sawant SD
Bioorg Med Chem Lett; 2018 Apr; 28(6):1005-1010. PubMed ID: 29486969
[TBL] [Abstract][Full Text] [Related]
30. Discovery of 1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-ones based novel, potent and PI3Kδ selective inhibitors.
Bahekar R; Dave B; Soman S; Patel D; Chopade R; Funde R; Kumar J; Sachchidanand S; Giri P; Chatterjee A; Mahapatra J; Vyas P; Ghoshdastidar K; Bandyopadhyay D; Desai RC
Bioorg Med Chem Lett; 2019 Jun; 29(11):1313-1319. PubMed ID: 30975623
[TBL] [Abstract][Full Text] [Related]
31. Idelalisib Impacts Cell Growth through Inhibiting Translation-Regulatory Mechanisms in Mantle Cell Lymphoma.
Yang Q; Chen LS; Ha MJ; Do KA; Neelapu SS; Gandhi V
Clin Cancer Res; 2017 Jan; 23(1):181-192. PubMed ID: 27342398
[TBL] [Abstract][Full Text] [Related]
32. Phosphoinositide 3-kinase δ inhibition promotes antitumor responses but antagonizes checkpoint inhibitors.
Lim EL; Cugliandolo FM; Rosner DR; Gyori D; Roychoudhuri R; Okkenhaug K
JCI Insight; 2018 Jun; 3(11):. PubMed ID: 29875319
[TBL] [Abstract][Full Text] [Related]
33. Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cells.
Compagno M; Wang Q; Pighi C; Cheong TC; Meng FL; Poggio T; Yeap LS; Karaca E; Blasco RB; Langellotto F; Ambrogio C; Voena C; Wiestner A; Kasar SN; Brown JR; Sun J; Wu CJ; Gostissa M; Alt FW; Chiarle R
Nature; 2017 Feb; 542(7642):489-493. PubMed ID: 28199309
[TBL] [Abstract][Full Text] [Related]
34. Distinct roles for phosphoinositide 3-kinases γ and δ in malignant B cell migration.
Ali AY; Wu X; Eissa N; Hou S; Ghia JE; Murooka TT; Banerji V; Johnston JB; Lin F; Gibson SB; Marshall AJ
Leukemia; 2018 Sep; 32(9):1958-1969. PubMed ID: 29479062
[TBL] [Abstract][Full Text] [Related]
35. The PI3Kδ-Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function Mediated by Rituximab or Obinutuzumab and Significantly Augments B Cell Depletion In Vivo.
Palazzo A; Herter S; Grosmaire L; Jones R; Frey CR; Limani F; Bacac M; Umana P; Oldham RJ; Marshall MJE; Cox KL; Turaj AH; Cragg MS; Klein C; Carter MJ; Tannheimer S
J Immunol; 2018 Apr; 200(7):2304-2312. PubMed ID: 29453281
[TBL] [Abstract][Full Text] [Related]
36. Targeting nonclassical oncogenes for therapy in T-ALL.
Subramaniam PS; Whye DW; Efimenko E; Chen J; Tosello V; De Keersmaecker K; Kashishian A; Thompson MA; Castillo M; Cordon-Cardo C; Davé UP; Ferrando A; Lannutti BJ; Diacovo TG
Cancer Cell; 2012 Apr; 21(4):459-72. PubMed ID: 22516257
[TBL] [Abstract][Full Text] [Related]
37. Discovery, Optimization, and Evaluation of Potent and Highly Selective PI3Kγ-PI3Kδ Dual Inhibitors.
Jia H; Dai G; Su W; Xiao K; Weng J; Zhang Z; Wang Q; Yuan T; Shi F; Zhang Z; Chen W; Sai Y; Wang J; Li X; Cai Y; Yu J; Ren P; Venable J; Rao T; Edwards JP; Bembenek SD
J Med Chem; 2019 May; 62(10):4936-4948. PubMed ID: 31033293
[TBL] [Abstract][Full Text] [Related]
38. Discovery of novel 1,3,5-triazine derivatives as potent inhibitor of cervical cancer via dual inhibition of PI3K/mTOR.
Hu J; Zhang Y; Tang N; Lu Y; Guo P; Huang Z
Bioorg Med Chem; 2021 Feb; 32():115997. PubMed ID: 33440319
[TBL] [Abstract][Full Text] [Related]
39. Structural, biochemical, and biophysical characterization of idelalisib binding to phosphoinositide 3-kinase δ.
Somoza JR; Koditek D; Villaseñor AG; Novikov N; Wong MH; Liclican A; Xing W; Lagpacan L; Wang R; Schultz BE; Papalia GA; Samuel D; Lad L; McGrath ME
J Biol Chem; 2015 Mar; 290(13):8439-46. PubMed ID: 25631052
[TBL] [Abstract][Full Text] [Related]
40. Design, synthesis and in vitro biological evaluation of 2-aminopyridine derivatives as novel PI3Kδ inhibitors for hematological cancer.
Yang C; Gong Y; Gao Y; Deng M; Liu X; Yang Y; Ling Y; Jia Y; Zhou Y
Bioorg Med Chem Lett; 2023 Feb; 82():129152. PubMed ID: 36706844
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
